0
Minerva Neurosciences, Inc Banner Image

Minerva Neurosciences, Inc

  • Ticker NERV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Minerva Neurosciences, Inc Logo Image
  • 11-50 Employees
  • Based in Waltham, Massachusetts
Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV”.
REPORT RATINGS
4.7 / 5.0 (115)

Minerva Neurosciences, Inc reports have an aggregate usefulness score of 4.7 based on 115 reviews.

Minerva Neurosciences, Inc

Most Recent Annual Report

Minerva Neurosciences, Inc
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Minerva Neurosciences, Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!